ABBV-085 specifically targets LRRC15, and this drug is currently undergoing a first-in-human phase I study (NCT02565758) for the treatment of sarcomas and other advanced solid tumors [39]; the preliminary results demonstrate its effectiveness in terms of antitumor activity. Here, LRRC15 is linked to sarcoma.